Recent mouse studies have shown that simvastatin can effectively treat inflammatory bowel disease by inhibiting NF-κB-induced IL-8 gene expression and blocking the transcriptional activity, phosphorylation, and DNA binding of NF-κB. This evidence concerns the gene CXCL8 and inflammatory bowel disease.